XLO Xilio Therapeutics, Inc.
Nasdaq · SEC CIK 1840233 · EDGAR
- Bought, last 12 months
- $43.9K 1 purchases by 1 insiders
- Sold, last 12 months
- $5,668 2 sales by 2 insiders
- Filings on record
- 108 since 2021-10-25, latest 2026-06-12 16:07
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Shannon James Samuel | Dir | $43.9K | — |
| Frankenfield Christopher James | CFO | — | $4,499 |
| Brennan Kevin M. | SVP, Fin AND ACCOUNTING | — | $1,169 |
| Luptakova Katarina | Chief MEDICAL Off | — | — |
| Russo Rene | Pres AND CEO, Dir | — | — |
Transactions 43
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | 2026-03-26 | XLO | Shannon James Samuel | Dir | P - Purchase | $8.79 | +5,000 | 10.0K | +100% | +$43.9K | |
| DT | 2026-01-05 | 2026-01-02 | XLO | Frankenfield Christopher James | CFO | S - Sale+OE | $0.64 | -7,030 | 24.8K | -22% | -$4,499 |
| DT | 2026-01-05 | 2026-01-01 | XLO | Frankenfield Christopher James | CFO | M - OptEx | — | +19.4K | 31.8K | +156% | — |
| DT | 2026-01-05 | 2026-01-01 | XLO | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | M - OptEx | — | +5,000 | 8,197 | +156% | — |
| DT | 2026-01-05 | 2026-01-02 | XLO | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | S - Sale+OE | $0.64 | -1,826 | 6,371 | -22% | -$1,169 |
| D | 2026-01-05 | 2026-01-01 | XLO | Russo Rene | Pres AND CEO, Dir | M - OptEx | — | +44.2K | 325.4K | +16% | — |
| D | 2026-01-05 | 2026-01-01 | XLO | Luptakova Katarina | Chief MEDICAL Off | M - OptEx | — | +16.6K | 33.2K | +100% | — |
| M | 2025-06-18 | 2025-06-16+ | XLO | Shannon James Samuel | Dir | P - Purchase | $0.69 | +70.0K | 70.0K | New | +$48.3K |
| 2025-06-18 | 2025-06-16 | XLO | Russo Rene | Pres AND CEO, Dir | P - Purchase | $0.68 | +36.3K | 281.2K | +15% | +$24.7K | |
| D | 2025-01-03 | 2025-01-01 | XLO | Frankenfield Christopher James | CFO | M - OptEx | — | +19.4K | 19.4K | New | — |
| D | 2025-01-03 | 2025-01-02 | XLO | Frankenfield Christopher James | CFO | S - Sale+OE | $0.98 | -6,954 | 12.4K | -36% | -$6,815 |
| D | 2025-01-03 | 2025-01-01 | XLO | Luptakova Katarina | Chief MEDICAL Off | M - OptEx | — | +16.6K | 16.6K | New | — |
| D | 2025-01-03 | 2025-01-01 | XLO | Russo Rene | Pres AND CEO, Dir | M - OptEx | — | +44.2K | 244.9K | +22% | — |
| D | 2025-01-03 | 2025-01-02 | XLO | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | S - Sale+OE | $0.98 | -1,803 | 3,197 | -36% | -$1,767 |
| D | 2025-01-03 | 2025-01-01 | XLO | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | M - OptEx | — | +5,000 | 5,000 | New | — |
| D | 2024-12-19 | 2024-12-18 | XLO | GILEAD SCIENCES, INC. | 10% | P - Purchase | $1.04 | +1.76M | 9.11M | +24% | +$1.83M |
| D | 2024-04-03 | 2024-04-02 | XLO | GILEAD SCIENCES, INC. | 10% | P - Purchase | $0.76 | +485.2K | 7.35M | +7% | +$368.8K |
| I | 2024-02-09 | 2024-02-08 | XLO | Atlas Venture Fund XI, L.P. | 10% | S - Sale | $0.64 | -267 | 734.5K | -0.0% | -$170.88 |
| 2024-02-09 | 2024-02-08 | XLO | Atlas Venture Fund XI, L.P. | 10% | S - Sale | $0.64 | -733 | 2.02M | -0.0% | -$469.12 | |
| M | 2024-01-16 | 2024-01-11+ | XLO | Atlas Venture Associates Opportunity I, L.P. | 10% | S - Sale | $0.8502 | -3,106 | 2.02M | -0.2% | -$2,641 |
| MI | 2024-01-16 | 2024-01-11+ | XLO | Atlas Venture Associates Opportunity I, L.P. | 10% | S - Sale | $0.8502 | -1,129 | 734.8K | -0.2% | -$959.83 |
| MI | 2021-12-10 | 2021-12-08+ | XLO | BCIP Life Sciences Associates, LP | 10% | P - Purchase | $9.66 | +42.5K | 2.78M | +2% | +$410.1K |
| DMAI | 2021-11-03 | 2021-10-26 | XLO | SV7 Impact Medicine Fund LP | 10% | C - Cnv Deriv | — | +1.30M | 1.30M | New | — |
| DMA | 2021-11-03 | 2021-10-26 | XLO | SV7 Impact Medicine Fund LP | 10% | C - Cnv Deriv | — | +1.30M | 1.30M | New | — |
| DA | 2021-11-03 | 2021-10-26 | XLO | SV7 Impact Medicine Fund LP | 10% | P - Purchase | $16.00 | +312.5K | 1.61M | +24% | +$5.00M |
| DAI | 2021-11-03 | 2021-10-26 | XLO | SV7 Impact Medicine Fund LP | 10% | P - Purchase | $16.00 | +312.5K | 1.61M | +24% | +$5.00M |
| DI | 2021-10-28 | 2021-10-26 | XLO | FIL Ltd | See Remark 1 | C - Cnv Deriv | — | +218.7K | 218.7K | New | — |
| DMI | 2021-10-28 | 2021-10-26 | XLO | FMR LLC | See Remark 1 | C - Cnv Deriv | — | +1.88M | 815.8K | New | — |
| DMI | 2021-10-28 | 2021-10-26 | XLO | Deerfield Mgmt L.P. | 10%, Possible Member of 10% Group | P - Purchase | $16.00 | +775.0K | 1.14M | +210% | +$12.40M |
| DMI | 2021-10-28 | 2021-10-26 | XLO | Deerfield Mgmt L.P. | 10%, Possible Member of 10% Group | C - Cnv Deriv | — | +1.51M | 756.5K | New | — |
| DM | 2021-10-28 | 2021-10-26 | XLO | SV7 (IMF) GP LLP | 10% | C - Cnv Deriv | — | +1.30M | 1.30M | New | — |
| DMI | 2021-10-28 | 2021-10-26 | XLO | SV7 (IMF) GP LLP | 10% | C - Cnv Deriv | — | +1.30M | 1.30M | New | — |
| DMI | 2021-10-26 | 2021-10-26 | XLO | Merck KGaA | 10% | C - Cnv Deriv | — | +680.8K | 416.1K | New | — |
| DI | 2021-10-26 | 2021-10-26 | XLO | Rock Springs Capital Master Fund LP | 10% | P - Purchase | $16.00 | +500.0K | 1.26M | +66% | +$8.00M |
| DMI | 2021-10-26 | 2021-10-26 | XLO | Rock Springs Capital Master Fund LP | 10% | C - Cnv Deriv | — | +907.8K | 756.5K | New | — |
| D | 2021-10-26 | 2021-10-26 | XLO | Alexandria Venture Investments, LLC | 10% | C - Cnv Deriv | — | +166.4K | 166.4K | New | — |
| DMI | 2021-10-26 | 2021-10-26 | XLO | Atlas Venture Opportunity Fund I, L.P. | 10% | C - Cnv Deriv | — | +2.55M | 1.40M | New | — |
| DI | 2021-10-26 | 2021-10-26 | XLO | Atlas Venture Opportunity Fund I, L.P. | 10% | P - Purchase | $16.00 | +187.5K | 735.9K | +34% | +$3.00M |
| DMI | 2021-10-26 | 2021-10-26 | XLO | RiverVest Venture Fund IV, L.P. | 10% | C - Cnv Deriv | — | +1.19M | 832.1K | New | — |
| DI | 2021-10-26 | 2021-10-26 | XLO | RiverVest Venture Fund IV, L.P. | 10% | P - Purchase | $16.00 | +250.0K | 1.44M | +21% | +$4.00M |
| DMI | 2021-10-26 | 2021-10-26 | XLO | BAY CITY CAPITAL LLC | 10% | C - Cnv Deriv | — | +817.0K | 665.7K | New | — |
| DI | 2021-10-26 | 2021-10-26 | XLO | BAY CITY CAPITAL LLC | 10% | P - Purchase | $16.00 | +312.5K | 1.13M | +38% | +$5.00M |
| DI | 2021-10-26 | 2021-10-26 | XLO | Takeda Ventures, Inc. | 10% | C - Cnv Deriv | — | +1.48M | 1.48M | New | — |
Purchase Sale Sale after option exercise All abbreviations